Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration

Area of Science:

• Oncology
• Pharmacology
• Clinical Pharmacy

Background:

• Docetaxel is a widely used chemotherapy agent.
• Simultaneous Y-site administration is common in clinical practice.
• Assessing drug compatibility is crucial for patient safety and effective treatment.

Purpose of the Study:

• To evaluate the physical compatibility of docetaxel with 81 secondary additives during simulated Y-site injection.
• To identify specific drugs that are incompatible with docetaxel under these conditions.

Main Methods:

• Docetaxel solutions were combined with 81 secondary additives (supportive-care drugs, anti-infectives).
• Visual inspection (unaided eye, Tyndall beam) and electronic turbidity measurements were used.
• Evaluations were conducted initially, and at one and four hours post-preparation.

Main Results:

• Docetaxel demonstrated physical compatibility with 78 of the 81 tested drugs.
• Incompatibilities were observed with Amphotericin B (increased haze), nalbuphine hydrochloride (sub-visual haze), and methylprednisolone sodium succinate (decreased natural haze).
• Turbidity changes were quantified using nephelometric turbidity units (NTU).

Conclusions:

• Simultaneous Y-site administration of docetaxel with amphotericin B, nalbuphine hydrochloride, or methylprednisolone sodium succinate should be avoided.
• Most supportive care and anti-infective drugs are compatible with docetaxel during Y-site administration.